Open AccessNeuroendocrine Cancer, Therapeutic Strategies in G3 Cancers
Author(s) -
Anja Rinke,
Thomas M. Gress
Publication year - 2017
Publication title -
digestion
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.882
H-Index - 75
eISSN - 1421-9867
pISSN - 0012-2823
DOI - 10.1159/000454761
Subject(s) - medicine , neuroendocrine tumors , etoposide , oncology , carboplatin , chemotherapy , regimen , irinotecan , cisplatin , temozolomide , gemcitabine , malignancy , chemotherapy regimen , cancer , colorectal cancer
According to the latest WHO classification, neuroendocrine neoplasm (NEN) G3 of the gastrointestinal tract is defined by a proliferation index Ki67 above 20%. Gastrointestinal neuroendocrine carcinoma (NEC) is a rare and highly aggressive malignancy and despite responsiveness to chemotherapy, overall survival is poor. In the last 3-4 years, the heterogeneity of the NEN G3 group has become evident.